More Evidence For Aspirin In Cancer Prevention

More evidence for aspirin in cancer prevention

More evidence for aspirin in cancer prevention

Friday, March 23, 2012. Articles published this week in The Lancet and The Lancet Oncology add evidence to a benefit for aspirin in protecting against cancer and preventing metastasis in pre-existing disease.

Professor Peter M Rothwell of the University of Oxford and his colleagues conducted the research described in all three reports. In the first article, Dr Rothwell's team analyzed data from 51 clinical trials that compared the effects of daily aspirin to no aspirin on the risk of cardiovascular events. They observed a 15 percent lower risk of dying of cancer over the course of the trials for those who received daily aspirin, which improved to a 37 percent reduction for those who received aspirin for five years or more. Cancer incidence was reduced as well, resulting in a 23 percent decrease in men and a 25 percent lower risk in women.

In the second Lancet study, Dr Rothwell and his associates reviewed five large trials that sought to determine the effect of daily aspirin on the effects of vascular events. Among 17,285 participants, 1,101 cases of cancer were diagnosed during the trials, including 563 fatal cases. Over an average 6.5 year follow up period, those who received aspirin had a 36 percent lower risk of being diagnosed with cancer with distant metastases, mainly due to a reduction in the proportion of metastatic versus nonmetastatic adenocarcinoma. Aspirin also reduced the risk of dying of cancer among adenocarcinoma patients. The effects were independent of gender and age, and were additionally observed in association with a low-dose, slow-release aspirin designed to inhibit platelets while having little systemic bioavailability. "That aspirin prevents metastasis at least partly accounts for the reduced cancer mortality recently reported in trials of aspirin versus control in prevention of vascular events and suggests that aspirin will also be effective in treatment of some cancers," the authors write. "The lack of dependence of this effect of aspirin on its systemic bioavailability suggests that it is platelet-mediated. Other antiplatelet drugs might therefore have a similar effect on risk of metastasis and combining different drugs might increase benefit."

The review published in The Lancet Oncology analyzed case-control and cohort studies that compared the risk of cancer experienced by aspirin and nonaspirin users. "Long-term follow-up of randomized trials of aspirin in prevention of vascular events showed that daily aspirin reduced the incidence of colorectal cancer and several other cancers and reduced metastasis," the authors write. "However, statistical power was inadequate to establish effects on less common cancers and on cancers in women. Observational studies could provide this information if results can be shown to be reliable. We therefore compared effects of aspirin on risk and outcome of cancer in observational studies versus randomized trials."

The results of these observational studies indicate a 38 percent lower risk of colorectal cancer over a 20 year period in association with aspirin use, which is in agreement with the reduction found in clinical trials. Similar decreases were found for esophageal, stomach, breast and biliary cancers.

In a commentary published in The Lancet, Dr Andrew T Chan and Dr Nancy R Cook of Brigham and Women's Hospital and Harvard Medical School write that "Rothwell and colleagues' impressive collection of data moves us another step closer to broadening recommendations for aspirin use. Moreover, future evidence-based guidelines for aspirin prophylaxis can no longer consider the use of aspirin for the prevention of vascular disease in isolation from cancer prevention."

What's Hot Highlight

Aspirin may be okay before heart surgery

What's Hot

While patients facing surgery are generally recommended to avoid aspirin due to the risk of increased bleeding, a study appearing online on October 12, 2011 in the Annals of Surgery has found that aspirin consumed prior to heart surgery is associated with a reduction in major postoperative complications and a lower risk of dying within the 30 day postoperative period.

Jianzhong Sun and colleagues studied the effect of aspirin on the outcome of 4,256 patients at the University of California Davis Medical Center and Thomas Jefferson University Hospital who underwent coronary artery bypass graft surgery or valve surgery between 2011 and 2009. One thousand nine hundred twenty-three subjects reported consuming aspirin at least once within five days of their surgery, in comparison with 945 who reported no aspirin use.

In the month following their surgeries, aspirin users experienced 34 percent fewer major events, including a 61.6 percent lower risk of renal failure, a 56 percent lower risk of needing dialysis and a 39 percent lower risk of premature mortality compared to those who did not use aspirin. Those who used aspirin also spent less time in intensive care. "We know that aspirin can be lifesaving for patients who have experienced heart attacks," stated coauthor Nilas Young, who is chief of cardiothoracic surgery at the University of California Davis Medical Center. "Now we know that this simple intervention can do the same for patients who undergo certain coronary surgeries. This outcome could lead to new preoperative treatment standards in cardiac medicine."

Thomas Jefferson University Hospital anesthesiology chair Zvi Grunwald added that "While we are excited that the study clearly showed that preoperative use of aspirin significantly reduced major complications and mortality in patients undergoing cardiac surgery, we do urge further study before recommending aspirin for cardiac surgery patients prior to surgery."

Life Extension Magazine® April, 2012 interactive version now live

Life Extension Magazine® January, 2012 interactive version now live

This e-issue of Life Extension Magazine® is extraordinarily easy to use, easy to navigate … with the same flip-the-page feeling you get from your printed copy, plus a few extra advantages. You can choose to search out a topic or keyword. Skim quickly. Skip ahead. Even order products. Now all that convenience is right at your fingertips.

As we see it: Lethal shortages, by William Faloon
Market manipulation and suffocating regulations are creating artificial shortages of life-saving drugs.

The overlooked role of probiotics in human health, by Joyce Killian
The new science of pharmabiotics substantiates the use of probiotic organisms as natural pharmaceutical-like agents in the battle against disease.

The CR Way to Great Glucose Control, by Paul McGlothin and Meredith Averill
The CR Way™ program enables people to enjoy low calorie meals and suppress after-meal (postprandial) surges in blood glucose.

Apple polyphenols and longevity, by George Randall
Apple polyphenols favorably modulate signaling molecules to delay the onset of age-related disorders.

Trimetazidine: The heart drug you've never heard of, by Carl DeMarco

Protect yourself during a nuclear emergency, by Roger Wilkinson

Activate self-renewing skin stem cells, by Gary Goldfaden, MD and Robert Goldfaden

Latest Supplements

Solarshield® Sunglasses
Item #00657

add to cart

Solarshields® block solar radiation in three ways:

  1. A unique top shield blocks direct overhead sun rays (like a brimmed hat).
  2. Wide side shields screen out peripheral sun rays while permitting protected side vision.
  3. A patented polycarbonate lens filters out 100% of UV sunlight.

Solarshields® provide more protection than conventional sunglasses and can be worn over most prescription eyeglasses. Solarshields are rated as 100% UV protected.


Super Selenium Complex
Item #00578

add to cart

As an essential cofactor of glutathione peroxidase, selenium is an important antioxidant. Selenium is incorporated into proteins to make selenoproteins, which are important antioxidant enzymes. The antioxidant properties of selenoproteins help prevent cellular damage from free radicals. Other selenoproteins help regulate thyroid function and play a role in the immune system, DNA repair, and the detoxification of heavy metals. High doses of vitamin C (over one gram) may enhance the absorption of selenium. This mineral is best taken in conjunction with antioxidant supplements, such as vitamins C or E.



Life Extension Update What's Hot
Aspirin use cuts hereditary cancer risk in half Aspirin use associated with reduced risk of prostate cancer recurrence
Low dose aspirin could help protect against death from cancer Aspirin users have lower pancreatic cancer risk
Daily aspirin reduces estrogen receptor positive breast cancer risk Aspirin combats tumor growth by inhibiting new blood vessel formation
Life Extension Magazine® Health Topics
The everyday drug that prevents cancer death Cancer adjuvant therapy
So many needless cancer deaths Breast cancer
Aspirin: remarkable research uncovers lifesaving benefits beyond cardiovascular protection Prostate cancer / prostate health